1
|
Oey O, Wijaya W, Redfern A. Eribulin in breast cancer: Current insights and therapeutic perspectives. World J Exp Med 2024; 14:92558. [PMID: 38948420 PMCID: PMC11212747 DOI: 10.5493/wjem.v14.i2.92558] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/29/2024] [Revised: 02/21/2024] [Accepted: 03/20/2024] [Indexed: 06/19/2024] Open
Abstract
Eribulin is a non-taxane synthetic analogue approved in many countries as third-line treatment for the treatment of patients with metastatic breast cancer. In addition to its mitotic property, eribulin has non-mitotic properties including but not limited to, its ability to induce phenotypic reversal of epithelial to mesenchymal transition, vascular remodelling, reduction in immunosuppressive tumour microenvironment. Since approval, there has been a surge in studies investigating the application of eribulin as an earlier-line treatment and also in combination with other agents such as immunotherapy and targeted therapy across all breast cancer sub-types, including hormone receptor positive, HER2 positive and triple negative breast cancer, many demonstrating promising activity. This review will focus on the application of eribulin in the treatment of metastatic breast cancer across all subtypes including its role as an earlier-line agent, its toxicity profile, and potential future directions.
Collapse
Affiliation(s)
- Oliver Oey
- Faculty of Medicine, University of Western Australia, Nedlands 6009, Australia
- Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands 6009, WA, Australia
| | - Wynne Wijaya
- Department of Oncology, University of Oxford, Oxford OX3 7DQ, United Kingdom
- Department of Internal Medicine, Universitas Gadjah Mada, Sleman 55281, Indonesia
| | - Andrew Redfern
- Department of Medical Oncology, Fiona Stanley Hospital, Murdoch 6150, WA, Australia
| |
Collapse
|
2
|
Iskandar M, Ruiz-Houston KM, Bracco SD, Sharkasi SR, Calabi Villarroel CL, Desai MN, Gerges AG, Ortiz Lopez NA, Xiao Barbero M, German AA, Moluguri VS, Walker SM, Silva Higashi J, Palma JM, Medina DZ, Patel M, Patel P, Valentin M, Diaz AC, Karthaka JP, Santiago AD, Skiles RB, Romero Umana LA, Ungrey MD, Wojtkowiak A, Howard DV, Nurge R, Woods KG, Nanjundan M. Deep-Sea Sponges and Corals off the Western Coast of Florida-Intracellular Mechanisms of Action of Bioactive Compounds and Technological Advances Supporting the Drug Discovery Pipeline. Mar Drugs 2023; 21:615. [PMID: 38132936 PMCID: PMC10744787 DOI: 10.3390/md21120615] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2023] [Revised: 11/20/2023] [Accepted: 11/21/2023] [Indexed: 12/23/2023] Open
Abstract
The majority of natural products utilized to treat a diverse array of human conditions and diseases are derived from terrestrial sources. In recent years, marine ecosystems have proven to be a valuable resource of diverse natural products that are generated to defend and support their growth. Such marine sources offer a large opportunity for the identification of novel compounds that may guide the future development of new drugs and therapies. Using the National Oceanic and Atmospheric Administration (NOAA) portal, we explore deep-sea coral and sponge species inhabiting a segment of the U.S. Exclusive Economic Zone, specifically off the western coast of Florida. This area spans ~100,000 km2, containing coral and sponge species at sea depths up to 3000 m. Utilizing PubMed, we uncovered current knowledge on and gaps across a subset of these sessile organisms with regards to their natural products and mechanisms of altering cytoskeleton, protein trafficking, and signaling pathways. Since the exploitation of such marine organisms could disrupt the marine ecosystem leading to supply issues that would limit the quantities of bioactive compounds, we surveyed methods and technological advances that are necessary for sustaining the drug discovery pipeline including in vitro aquaculture systems and preserving our natural ecological community in the future. Collectively, our efforts establish the foundation for supporting future research on the identification of marine-based natural products and their mechanism of action to develop novel drugs and therapies for improving treatment regimens of human conditions and diseases.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Meera Nanjundan
- Department of Molecular Biosciences, University of South Florida, 4202 East Fowler Avenue, ISA2015, Tampa, FL 33620, USA; (M.I.); (K.M.R.-H.); (S.D.B.); (S.R.S.); (C.L.C.V.); (M.N.D.); (A.G.G.); (N.A.O.L.); (M.X.B.); (A.A.G.); (V.S.M.); (S.M.W.); (J.S.H.); (J.M.P.); (D.Z.M.); (M.P.); (P.P.); (M.V.); (A.C.D.); (J.P.K.); (A.D.S.); (R.B.S.); (L.A.R.U.); (M.D.U.); (A.W.); (D.V.H.); (R.N.); (K.G.W.)
| |
Collapse
|
3
|
Chaurasia M, Singh R, Sur S, Flora SJS. A review of FDA approved drugs and their formulations for the treatment of breast cancer. Front Pharmacol 2023; 14:1184472. [PMID: 37576816 PMCID: PMC10416257 DOI: 10.3389/fphar.2023.1184472] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2023] [Accepted: 06/23/2023] [Indexed: 08/15/2023] Open
Abstract
Breast cancer is one of the most diagnosed solid cancers globally. Extensive research has been going on for decades to meet the challenges of treating solid tumors with selective compounds. This article aims to summarize the therapeutic agents which are either being used or are currently under approval for use in the treatment or mitigation of breast cancer by the US FDA, to date. A structured search of bibliographic databases for previously published peer-reviewed research papers on registered molecules was explored and data was sorted in terms of various categories of drugs used in first line/adjuvant therapy for different stages of breast cancer. We included more than 300 peer-reviewed papers, including both research and reviews articles, in order to provide readers an useful comprehensive information. A list of 39 drugs are discussed along with their current status, dose protocols, mechanism of action, pharmacokinetics, possible side effects, and marketed formulations. Another interesting aspect of the article included focusing on novel formulations of these drugs which are currently in clinical trials or in the process of approval. This exhaustive review thus shall be a one-stop solution for researchers who are working in the areas of formulation development for these drugs.
Collapse
Affiliation(s)
| | | | | | - S. J. S. Flora
- Era College of Pharmacy, Era University, Lucknow, Uttar Pradesh, India
| |
Collapse
|
4
|
Jenkins AP, Lancaster AMSN, Capon A, Soapi K, Fleming LE, Jupiter SD. Human health depends on thriving oceans. Lancet 2023; 402:9-11. [PMID: 37301212 DOI: 10.1016/s0140-6736(23)01162-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/02/2023] [Accepted: 06/02/2023] [Indexed: 06/12/2023]
Affiliation(s)
- Aaron P Jenkins
- Centre for People, Place and Planet, Edith Cowan University, Perth, WA 6027, Australia; School of Public Health, University of Sydney, Sydney, NSW, Australia.
| | - Alana M S N Lancaster
- Faculty of Law, University of the West Indies, Cave Hill, Barbados; One Ocean Hub, University of Strathclyde, Glasgow, UK
| | - Anthony Capon
- Monash Sustainable Development Institute, Monash University, Melbourne, VIC, Australia
| | - Katy Soapi
- The Pacific Community Centre for Ocean Science, The Pacific Community, Suva, Fiji
| | - Lora E Fleming
- European Centre for Environment and Human Health, University of Exeter Medical School, Truro, UK
| | - Stacy D Jupiter
- Wildlife Conservation Society, Melanesia Program, Suva, Fiji
| |
Collapse
|
5
|
Yu Q, Zhou Y, Gao X, Pan S, Lin F, Li W. Gram-Scale Synthesis of the C14–C23 Fragment of Eribulin. Org Process Res Dev 2023. [DOI: 10.1021/acs.oprd.2c00370] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Affiliation(s)
- Qiuhan Yu
- Department of Medicinal Chemistry School of Pharmacy, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, Jiangsu 211198, P. R. of China
| | - Yueer Zhou
- Department of Medicinal Chemistry School of Pharmacy, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, Jiangsu 211198, P. R. of China
| | - Xinai Gao
- Department of Medicinal Chemistry School of Pharmacy, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, Jiangsu 211198, P. R. of China
| | - Shuheng Pan
- Department of Medicinal Chemistry School of Pharmacy, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, Jiangsu 211198, P. R. of China
| | - Feng Lin
- WuXi AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, P. R. of China
| | - Wei Li
- Department of Medicinal Chemistry School of Pharmacy, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, Jiangsu 211198, P. R. of China
| |
Collapse
|
6
|
Stellettin B Induces Cell Death in Bladder Cancer Via Activating the Autophagy/DAPK2/Apoptosis Signaling Cascade. Mar Drugs 2023; 21:md21020073. [PMID: 36827114 PMCID: PMC9966069 DOI: 10.3390/md21020073] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2022] [Revised: 01/18/2023] [Accepted: 01/19/2023] [Indexed: 01/24/2023] Open
Abstract
Bladder cancer (BC) is one of the most prevalent cancers worldwide. However, the recurrence rate and five-year survival rate have not been significantly improved in advanced BC, and new therapeutic strategies are urgently needed. The anticancer activity of stellettin B (SP-2), a triterpene isolated from the marine sponge Rhabdastrella sp., was evaluated with the MTT assay as well as PI and Annexin V/7-AAD staining. Detailed mechanisms were elucidated through an NGS analysis, protein arrays, and Western blotting. SP-2 suppressed the viability of BC cells without severe toxicity towards normal uroepithelial cells, and it increased apoptosis with the activation of caspase 3/8/9, PARP, and γH2AX. The phosphorylation of FGFR3 and its downstream targets were downregulated by SP-2. Meanwhile, it induced autophagy in BC cells as evidenced by LC3-II formation and p62 downregulation. The inhibition of autophagy using pharmacological inhibitors or through an ATG5-knockout protected RT-112 cells from SP-2-induced cell viability suppression and apoptosis. In addition, the upregulation of DAPK2 mRNA and protein expression also contributed to SP-2-induced cytotoxicity and apoptosis. In RT-112 cells, an FGFR3-TACC3-knockout caused the downregulation of DAPK2, autophagy, and apoptosis. In conclusion, this is the first study demonstrating that SP-2 exhibits potent anti-BC activity by suppressing the FGFR3-TACC3/Akt/mTOR pathway, which further activates a novel autophagy/DAPK2/apoptosis signaling cascade.
Collapse
|
7
|
A unified strategy for the total syntheses of eribulin and a macrolactam analogue of halichondrin B. Proc Natl Acad Sci U S A 2022; 119:e2208938119. [PMID: 35930662 PMCID: PMC9371655 DOI: 10.1073/pnas.2208938119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
A unified synthetic route for the total syntheses of eribulin and a macrolactam analog of halichondrin B is described. The key to the success of the current synthetic approach includes the employment of our reverse approach for the construction of cyclic ether structural motifs and a modified intramolecular cyclization reaction between alkyl iodide and aldehyde functionalities to establish the all-carbon macrocyclic framework of eribulin. These syntheses, together with our previous work on the total syntheses of halichondrin B and norhalichondrin B, demonstrate and validate the powerful reverse approach in the construction of cyclic ether structural motifs. On the other hand, the unified synthetic strategy for the synthesis of the related macrolactam analog provides inspiration and opportunities in the halichondrin field and related polycyclic ether areas.
Collapse
|
8
|
Phillips E, Jones RL, Huang P, Digklia A. Efficacy of Eribulin in Soft Tissue Sarcomas. Front Pharmacol 2022; 13:869754. [PMID: 35444542 PMCID: PMC9014307 DOI: 10.3389/fphar.2022.869754] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2022] [Accepted: 03/14/2022] [Indexed: 11/13/2022] Open
Abstract
Soft tissue sarcomas are a highly heterogenous group of tumors with limited systemic therapy options. Eribulin, a synthetic analogue of halichondrin B, is a potent mitotic inhibitor. A phase 3 trial of previously treated advanced Liposarcoma and Leiomyosarcoma demonstrated superiority of eribulin to dacarbazine. Eribulin appears to be particularly effective for liposarcomas. It has also been shown to be a safe and effective treatment alternative to doxorubicin in patients where doxorubicin is contraindicated. From retrospective studies, eribulin has demonstrated efficacy in patients with angiosarcoma, pleomorphic sarcomas, synovial sarcomas, rhabdomyosarcomas, angiosarcomas, and myxofibrosarcomas. Future areas of development include liposomal eribulin, which may provide increased efficacy and lower toxicity, and delineation of biomarkers of response and resistance, allowing better selection of patients for treatment.
Collapse
Affiliation(s)
| | - Robin L Jones
- Royal Marsden Hospital, London, United Kingdom.,Royal Marsden Hospital, Division of Clinical Sciences, Institute of Cancer Research, London, United Kingdom
| | - Paul Huang
- Division of Molecular Pathology, Institute of Cancer Research, London, United Kingdom
| | - Antonia Digklia
- Department of Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| |
Collapse
|
9
|
Kaur M, Kaur M, Bandopadhyay T, Sharma A, Priya A, Singh A, Banerjee B. Naturally occurring, natural product inspired and synthetic heterocyclic anti-cancer drugs. PHYSICAL SCIENCES REVIEWS 2022. [DOI: 10.1515/psr-2022-0003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Abstract
This chapter describes the importance and activity of a huge number of commercially available naturally occurring, natural product derived or synthetic heterocyclic anti-cancer drugs.
Collapse
Affiliation(s)
- Manmeet Kaur
- Department of Chemistry , Akal University , Talwandi Sabo , Bathinda , Punjab 151302 , India
| | - Mandeep Kaur
- Department of Chemistry , Akal University , Talwandi Sabo , Bathinda , Punjab 151302 , India
| | - Tania Bandopadhyay
- Completed MBBS from North Bengal Medical College and Hospital , Darjeeling , West Bengal , Pin-734432 , India
| | - Aditi Sharma
- Department of Chemistry , Akal University , Talwandi Sabo , Bathinda , Punjab 151302 , India
| | - Anu Priya
- Department of Chemistry , Akal University , Talwandi Sabo , Bathinda , Punjab 151302 , India
| | - Arvind Singh
- Department of Chemistry , Akal University , Talwandi Sabo , Bathinda , Punjab 151302 , India
| | - Bubun Banerjee
- Department of Chemistry , Akal University , Talwandi Sabo , Bathinda , Punjab 151302 , India
| |
Collapse
|
10
|
Kim ST, Park Y, Kim N, Gu J, Son W, Hur J, Lee K, Baek A, Song JY, Kim UB, Lee KY, Oh CY, Park S, Shin H. Synthesis of the C1–C13 Fragment of Eribulin on a Kilogram Scale. Org Process Res Dev 2021. [DOI: 10.1021/acs.oprd.1c00295] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Seong Taek Kim
- R&D Center, Yonsung Fine Chemicals Company Limited, Innoplex-2-dong, 306, Sinwon-ro, Yeongtong-gu, Suwon-si 16675, Gyeonggi-do, Republic of Korea
| | - Yongseo Park
- R&D Center, Yonsung Fine Chemicals Company Limited, Innoplex-2-dong, 306, Sinwon-ro, Yeongtong-gu, Suwon-si 16675, Gyeonggi-do, Republic of Korea
| | - Namhyeon Kim
- R&D Center, Yonsung Fine Chemicals Company Limited, Innoplex-2-dong, 306, Sinwon-ro, Yeongtong-gu, Suwon-si 16675, Gyeonggi-do, Republic of Korea
| | - Jaeun Gu
- R&D Center, Yonsung Fine Chemicals Company Limited, Innoplex-2-dong, 306, Sinwon-ro, Yeongtong-gu, Suwon-si 16675, Gyeonggi-do, Republic of Korea
| | - Wongyoung Son
- R&D Center, Yonsung Fine Chemicals Company Limited, Innoplex-2-dong, 306, Sinwon-ro, Yeongtong-gu, Suwon-si 16675, Gyeonggi-do, Republic of Korea
| | - Jisu Hur
- R&D Center, Yonsung Fine Chemicals Company Limited, Innoplex-2-dong, 306, Sinwon-ro, Yeongtong-gu, Suwon-si 16675, Gyeonggi-do, Republic of Korea
| | - KangHee Lee
- R&D Center, Yonsung Fine Chemicals Company Limited, Innoplex-2-dong, 306, Sinwon-ro, Yeongtong-gu, Suwon-si 16675, Gyeonggi-do, Republic of Korea
| | - Areum Baek
- R&D Center, Yonsung Fine Chemicals Company Limited, Innoplex-2-dong, 306, Sinwon-ro, Yeongtong-gu, Suwon-si 16675, Gyeonggi-do, Republic of Korea
| | - Ju Young Song
- R&D Center, Yonsung Fine Chemicals Company Limited, Innoplex-2-dong, 306, Sinwon-ro, Yeongtong-gu, Suwon-si 16675, Gyeonggi-do, Republic of Korea
| | - U Bin Kim
- R&D Center, Yonsung Fine Chemicals Company Limited, Innoplex-2-dong, 306, Sinwon-ro, Yeongtong-gu, Suwon-si 16675, Gyeonggi-do, Republic of Korea
| | - Kee-Young Lee
- R&D Center, Yonsung Fine Chemicals Company Limited, Innoplex-2-dong, 306, Sinwon-ro, Yeongtong-gu, Suwon-si 16675, Gyeonggi-do, Republic of Korea
| | - Chang-Young Oh
- R&D Center, Yonsung Fine Chemicals Company Limited, Innoplex-2-dong, 306, Sinwon-ro, Yeongtong-gu, Suwon-si 16675, Gyeonggi-do, Republic of Korea
| | - Seokhwi Park
- R&D Center, Yonsung Fine Chemicals Company Limited, Innoplex-2-dong, 306, Sinwon-ro, Yeongtong-gu, Suwon-si 16675, Gyeonggi-do, Republic of Korea
| | - Hyunik Shin
- R&D Center, Yonsung Fine Chemicals Company Limited, Innoplex-2-dong, 306, Sinwon-ro, Yeongtong-gu, Suwon-si 16675, Gyeonggi-do, Republic of Korea
| |
Collapse
|
11
|
Cappello E, Nieri P. From Life in the Sea to the Clinic: The Marine Drugs Approved and under Clinical Trial. Life (Basel) 2021; 11:1390. [PMID: 34947921 PMCID: PMC8704254 DOI: 10.3390/life11121390] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2021] [Revised: 11/30/2021] [Accepted: 12/07/2021] [Indexed: 12/13/2022] Open
Abstract
In the last decades Blue Growth policy in european and non-european countries produced a great impulse in applied marine sciences, comprehending the research of new bioactive molecules in marine organisms. These organisms are a great source of natural compounds with unique features resulting from the huge variability of marine habitats and species living in them. Most of the marine compounds in use and in clinical trials are drugs for cancer therapy and many of them are conjugated to antibody to form antibody-drug conjugates (ADCs). Severe pain, viral infections, hypertriglyceridemia, obesity, Alzheimer's and other CNS diseases are further target conditions for these pharmaceuticals. This review summarizes the state-of-the-art marine drugs focusing on the most successful results in the fast expanding field of marine pharmacology.
Collapse
Affiliation(s)
- Emiliano Cappello
- Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy
| | - Paola Nieri
- Department of Pharmacy, University of Pisa, 56126 Pisa, Italy;
- Interdepartmental Center of Marine Pharmacology (MARinePHARMA), University of Pisa, 56126 Pisa, Italy
| |
Collapse
|
12
|
Kumar Mallurwar N, Khatravath M, Konda S, Thatikonda T, Iqbal J, Arya P. Stereoselective Approaches for Building the C14‐C21 Fragment of Eribulin. ChemistrySelect 2021. [DOI: 10.1002/slct.202004001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Naveen Kumar Mallurwar
- Dr. Reddy's Institute of Life Sciences University of Hyderabad Campus, Gachibowli Hyderabad, Telangana 500046 India
| | - Mahender Khatravath
- Central university of South Bihar, Gaya, SH-7, Panchanpur Road, Karhara, Post: Fatehpur Gaya, Bihar 824236 India
- Dr. Reddy's Institute of Life Sciences University of Hyderabad Campus, Gachibowli Hyderabad, Telangana 500046 India
| | - Saidulu Konda
- Dr. Reddy's Institute of Life Sciences University of Hyderabad Campus, Gachibowli Hyderabad, Telangana 500046 India
| | - Thanusha Thatikonda
- Institute of Organic Chemistry Polish Academy of Sciences 01-224 Warsaw Poland
| | - Javed Iqbal
- Institute of Organic Chemistry Polish Academy of Sciences 01-224 Warsaw Poland
| | - Prabhat Arya
- Dr. Reddy's Institute of Life Sciences University of Hyderabad Campus, Gachibowli Hyderabad, Telangana 500046 India
- SignMod-Transcell University of Hyderabad Campus, Gachibowli Hyderabad 500046 India
| |
Collapse
|
13
|
Design and Synthesis of Anti-Cancer Chimera Molecules Based on Marine Natural Products. Mar Drugs 2019; 17:md17090500. [PMID: 31461968 PMCID: PMC6780274 DOI: 10.3390/md17090500] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2019] [Revised: 08/07/2019] [Accepted: 08/16/2019] [Indexed: 12/16/2022] Open
Abstract
In this paper, the chemical conjugation of marine natural products with other bioactive molecules for developing an advanced anti-cancer agent is described. Structural complexity and the extraordinary biological features of marine natural products have led to tremendous research in isolation, structural elucidation, synthesis, and pharmacological evaluation. In addition, this basic scientific achievement has made it possible to hybridize two or more biologically important skeletons into a single compound. The hybridization strategy has been used to identify further opportunities to overcome certain limitations, such as structural complexity, scarcity problems, poor solubility, severe toxicity, and weak potency of marine natural products for advanced development in drug discovery. Further, well-designed marine chimera molecules can function as a platform for target discovery or degradation. In this review, the design, synthesis, and biological evaluation of recent marine chimera molecules are presented.
Collapse
|
14
|
Kumar A, Jaitak V. Natural products as multidrug resistance modulators in cancer. Eur J Med Chem 2019; 176:268-291. [PMID: 31103904 DOI: 10.1016/j.ejmech.2019.05.027] [Citation(s) in RCA: 199] [Impact Index Per Article: 39.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2019] [Revised: 05/07/2019] [Accepted: 05/07/2019] [Indexed: 01/21/2023]
Abstract
Cancer is a prominent cause of death globally. Currently, many drugs that are in clinical practice are having a high prevalence of side effect and multidrug resistance. Risk of tumors acquiring resistance to chemotherapy (multidrug resistance) remains a significant hurdle to the successful treatment of various types of cancer. Membrane-embedded drug transporters, generally overexpressed in cancer, are the leading cause among multiple mechanisms of multidrug resistance (MDR). P-glycoprotein (P-gp) also MDR1/ABCB1, multidrug resistance associated protein 1 (MRP1/ABCC1), MRP2 and breast cancer resistance protein (BCRP/ABCG2) are considered to be a prime factor for induction of MDR. To date, several chemical substances have been tested in a number of clinical trials for their MDR modulatory activity which are not having devoid of any side effects that necessitates to find newer and safer way to tackle the current problem of multidrug resistance in cancer. The present study systematically discusses the various classes of natural products i.e flavonoids, alkaloids, terpenoids, coumarins (from plants, marine, and microorganisms) as potential MDR modulators and/or as a source of promising lead compounds. Recently a bisbenzyl isoquinoline alkaloid namely tetrandrine, isolated from Chinese herb Stephania tetrandra (Han-Fang-Chi) is in clinical trials for its MDR reversal activity.
Collapse
Affiliation(s)
- Amit Kumar
- Laboratory of Natural Products, Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Mansa Road, Bathinda, 151001, India
| | - Vikas Jaitak
- Laboratory of Natural Products, Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Mansa Road, Bathinda, 151001, India.
| |
Collapse
|
15
|
Anti-tubulin agents of natural origin: Targeting taxol, vinca, and colchicine binding domains. Eur J Med Chem 2019; 171:310-331. [PMID: 30953881 DOI: 10.1016/j.ejmech.2019.03.025] [Citation(s) in RCA: 114] [Impact Index Per Article: 22.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2019] [Revised: 03/09/2019] [Accepted: 03/10/2019] [Indexed: 12/24/2022]
Abstract
Microtubules are a protein which is made of α- and β-heterodimer. It is one of the main components of the cell which play a vital role in cell division especially in G2/M-phase. It exists in equilibrium dynamic of polymerization and depolymerization of α- and β-heterodimer. It is one of the best targets for developing anti-cancer drugs. Various natural occurring molecules are well known for their anti-tubulin effect such as vinca, paclitaxel, combretastatin, colchicine etc. These microtubule-targeted drugs are acted through two processes (i) inhibiting depolymerization of tubulin (tubulin stabilizing agents) and (ii) inhibiting polymerization of tubulin (tubulin destabilizing agents). Now days, various binding domains have been explore through which these molecules are binding to tubulin but the three major binding domain of tubulin are taxol, vinca and colchicine binding domain. The present article mainly focus on the classification of various naturally occurring compounds on the basis of their inhibition processes (depolymerization and polymerization) and the site of interaction (targets taxol, vinca and colchicine binding domain) which has been hitherto reported. By placing all the naturally occurring taxol, vinca and colchicine binding site analogues at one place makes a better understanding of the tubulin interactions with known natural tubulin binders that would helps in the discovery of new and potent natural, semi-synthetic and synthetic analogues for treating cancer.
Collapse
|
16
|
Delost MD, Smith DT, Anderson BJ, Njardarson JT. From Oxiranes to Oligomers: Architectures of U.S. FDA Approved Pharmaceuticals Containing Oxygen Heterocycles. J Med Chem 2018; 61:10996-11020. [PMID: 30024747 DOI: 10.1021/acs.jmedchem.8b00876] [Citation(s) in RCA: 191] [Impact Index Per Article: 31.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Oxygen heterocycles are the second most common type of heterocycles that appear as structural components of U.S. Food and Drug Administration (FDA) approved pharmaceuticals. Analysis of our database of drugs approved through 2017 reveals 311 distinct pharmaceuticals containing at least one oxygen heterocycle. Most prevalent among these are pyranoses, with furanoses, macrolactones, morpholines, and dioxolanes rounding off the top five. The main body of this Perspective is organized according to ring size, commencing with three- and four-membered rings and ending with macrocycles, polymers, and unusual oxygen-containing heterocycles. For each section, all oxygen heterocycle-containing drugs are presented along with a brief discussion about structural and drug application patterns.
Collapse
Affiliation(s)
- Michael D Delost
- Department of Chemistry and Biochemistry , University of Arizona , 1306 E. University Boulevard , Tucson , Arizona 85721 , United States
| | - David T Smith
- Department of Chemistry and Biochemistry , University of Arizona , 1306 E. University Boulevard , Tucson , Arizona 85721 , United States
| | - Benton J Anderson
- Department of Chemistry and Biochemistry , University of Arizona , 1306 E. University Boulevard , Tucson , Arizona 85721 , United States
| | - Jon T Njardarson
- Department of Chemistry and Biochemistry , University of Arizona , 1306 E. University Boulevard , Tucson , Arizona 85721 , United States
| |
Collapse
|
17
|
Koliou P, Karavasilis V, Theochari M, Pollack SM, Jones RL, Thway K. Advances in the treatment of soft tissue sarcoma: focus on eribulin. Cancer Manag Res 2018; 10:207-216. [PMID: 29440930 PMCID: PMC5798537 DOI: 10.2147/cmar.s143019] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Eribulin mesylate is a synthetic derivative of halichondrin B isolated from a marine sponge. Its mechanism of action is through microtubule inhibition, which is different from that of taxanes. Eribulin has been approved for the treatment of metastatic breast cancer and more recently for non-operable or metastatic liposarcoma in patients who have received prior anthracycline chemotherapy. The major side effects of eribulin are bone marrow suppression including neutropenia, leukopenia, anemia, and fatigue/weakness, which can be well managed. In this article, we reviewed evidence from the latest published data on eribulin and its use in the treatment of soft tissue sarcomas. We explored the drug’s mechanism of action, pharmacodynamics, pharmacokinetics, and metabolism. Lastly, we reviewed all preclinical studies as well as clinical trials that investigated eribulin.
Collapse
Affiliation(s)
- Panagiotis Koliou
- The London Sarcoma Service, University College London Hospital, London, UK
| | | | | | - Seth M Pollack
- Division of Oncology, University of Washington, Seattle, WA, USA
| | | | | |
Collapse
|
18
|
Sabatier R, Diéras V, Pivot X, Brain E, Roché H, Extra JM, Monneur A, Provansal M, Tarpin C, Bertucci F, Viens P, Zemmour C, Gonçalves A. Safety Results and Analysis of Eribulin Efficacy according to Previous Microtubules-Inhibitors Sensitivity in the French Prospective Expanded Access Program for Heavily Pre-treated Metastatic Breast Cancer. Cancer Res Treat 2017; 50:1226-1237. [PMID: 29281873 PMCID: PMC6192912 DOI: 10.4143/crt.2017.446] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2017] [Accepted: 12/26/2017] [Indexed: 02/06/2023] Open
Abstract
Purpose Eribulin is approved for advanced breast cancers refractory to anthracyclines and taxanes. Efficacy according to sensitivity to previous therapies has been poorly explored. Materials and Methods Safety data were collected prospectively and we retrospectively collected efficacy data from the five French centres that participated in the Eribulin E7389-G000-398 expanded access program. Our main objectives were exploration of safety and analysis of eribulin efficacy (progression-free survival [PFS] and overall survival [OS]) according to sensitivity to the last microtubule-inhibiting agent administered. Results Median eribulin treatment duration was 3.3 months for the 250 patients included in this prospective single-arm study. Two hundreds and thirty-nine patients (95.6%) experienced an adverse event (AE) related to treatment including 129 (51.6%) with grade ≥ 3 AEs. The most frequently observed toxicities were cytopenias (59.6% of included patients), gastro-intestinal disorders (59.2%), and asthenia (56.4%). The most frequent grade 3-4 AE was neutropenia (37.2% with 4.8% febrile neutropenia). Median PFS and OS were 4.6 and 11.8 months, respectively. Patients classified as responders to the last microtubule-inhibiting therapy had a longer OS (hazard ratio [HR], 0.69; 95% confidence interval [CI], 0.51 to 0.94; p=0.017), and tended to display a better PFS (HR, 0.78; 95% CI, 0.58 to 1.04; p=0.086). OS improvement was still significant in multivariate analysis (adjusted HR, 0.53; 95% CI, 0.35 to 0.79; p=0.002). Conclusion This work based on a prospective study suggests that identification of patients likely to be more sensitive to eribulin could be based on their previous response to microtubules
inhibitors.
Collapse
Affiliation(s)
- Renaud Sabatier
- Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.,Aix Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France
| | | | - Xavier Pivot
- University Hospital Jean Minjoz, INSERM, Besançon, France
| | - Etienne Brain
- Institut Curie-Hôpital René Huguenin, Saint-Cloud, France
| | - Henri Roché
- Institut Claudius-Regaud, IUCT-oncopole, Université Paul-Sabatier, Toulouse, France
| | - Jean-Marc Extra
- Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France
| | - Audrey Monneur
- Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.,Aix Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France
| | - Magali Provansal
- Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France
| | - Carole Tarpin
- Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France
| | - François Bertucci
- Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.,Aix Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France
| | - Patrice Viens
- Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.,Aix Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France
| | - Christophe Zemmour
- Department of Clinical Research and Innovation, Biostatistics Unit, Institut Paoli-Calmettes, Marseille, France.,Aix Marseille University, INSERM, IRD, SESSTIM, Marseille, France
| | - Anthony Gonçalves
- Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.,Aix Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France
| |
Collapse
|
19
|
Mioso R, Marante FJT, Bezerra RDS, Borges FVP, Santos BVDO, Laguna IHBD. Cytotoxic Compounds Derived from Marine Sponges. A Review (2010-2012). Molecules 2017; 22:E208. [PMID: 28134844 PMCID: PMC6155849 DOI: 10.3390/molecules22020208] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2016] [Revised: 01/11/2017] [Accepted: 01/17/2017] [Indexed: 12/20/2022] Open
Abstract
Abstract: This extensive review covers research published between 2010 and 2012 regarding new compounds derived from marine sponges, including 62 species from 60 genera belonging to 33 families and 13 orders of the Demospongia class (Porifera). The emphasis is on the cytotoxic activity that bioactive metabolites from sponges may have on cancer cell lines. At least 197 novel chemical structures from 337 compounds isolated have been found to support this work. Details on the source and taxonomy of the sponges, their geographical occurrence, and a range of chemical structures are presented. The compounds discovered from the reviewed marine sponges fall into mainly four chemical classes: terpenoids (41.9%), alkaloids (26.2%), macrolides (8.9%) and peptides (6.3%) which, along with polyketides, sterols, and others show a range of biological activities. The key sponge orders studied in the reviewed research were Dictyoceratida, Haplosclerida, Tetractinellida, Poecilosclerida, and Agelasida. Petrosia, Haliclona (Haplosclerida), Rhabdastrella (Tetractinellida), Coscinoderma and Hyppospongia (Dictyioceratida), were found to be the most promising genera because of their capacity for producing new bioactive compounds. Several of the new compounds and their synthetic analogues have shown in vitro cytotoxic and pro-apoptotic activities against various tumor/cancer cell lines, and some of them will undergo further in vivo evaluation.
Collapse
Affiliation(s)
- Roberto Mioso
- Laboratory of Enzymology - LABENZ, Department of Biochemistry, Federal University of Pernambuco, Recife 50670-901, Pernambuco, Brazil.
| | - Francisco J Toledo Marante
- Department of Chemistry, University of Las Palmas de Gran Canaria, Las Palmas de Gran Canaria 35017, Spain.
| | - Ranilson de Souza Bezerra
- Laboratory of Enzymology - LABENZ, Department of Biochemistry, Federal University of Pernambuco, Recife 50670-901, Pernambuco, Brazil.
| | - Flávio Valadares Pereira Borges
- Post-Graduation Program in Natural Products and Synthetic Bioactives, Federal University of Paraíba, João Pessoa 58051-970, Paraíba, Brazil.
| | - Bárbara V de Oliveira Santos
- Post-Graduation Program in Development and Technological Innovation in Medicines, Department of Pharmaceutical Sciences, Federal University of Paraiba, João Pessoa 58051-900, Paraíba, Brazil.
| | | |
Collapse
|
20
|
Phylogenetic Tree Analysis of the Cold-Hot Nature of Traditional Chinese Marine Medicine for Possible Anticancer Activity. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE 2017; 2017:4365715. [PMID: 28191021 PMCID: PMC5278566 DOI: 10.1155/2017/4365715] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/30/2016] [Revised: 10/30/2016] [Accepted: 12/04/2016] [Indexed: 11/25/2022]
Abstract
Traditional Chinese Marine Medicine (TCMM) represents one of the medicinal resources for research and development of novel anticancer drugs. In this study, to investigate the presence of anticancer activity (AA) displayed by cold or hot nature of TCMM, we analyzed the association relationship and the distribution regularity of TCMMs with different nature (613 TCMMs originated from 1,091 species of marine organisms) via association rules mining and phylogenetic tree analysis. The screened association rules were collected from three taxonomy groups: (1) Bacteria superkingdom, Phaeophyceae class, Fucales order, Sargassaceae family, and Sargassum genus; (2) Viridiplantae kingdom, Streptophyta phylum, Malpighiales class, and Rhizophoraceae family; (3) Holothuroidea class, Aspidochirotida order, and Holothuria genus. Our analyses showed that TCMMs with closer taxonomic relationship were more likely to possess anticancer bioactivity. We found that the cluster pattern of marine organisms with reported AA tended to cluster with cold nature TCMMs. Moreover, TCMMs with salty-cold nature demonstrated properties for softening hard mass and removing stasis to treat cancers, and species within Metazoa or Viridiplantae kingdom of cold nature were more likely to contain AA properties. We propose that TCMMs from these marine groups may enable focused bioprospecting for discovery of novel anticancer drugs derived from marine bioresources.
Collapse
|
21
|
Choi H, Cho SY, Pak HJ, Kim Y, Choi JY, Lee YJ, Gong BH, Kang YS, Han T, Choi G, Cho Y, Lee S, Ryoo D, Park H. NPCARE: database of natural products and fractional extracts for cancer regulation. J Cheminform 2017; 9:2. [PMID: 28184254 PMCID: PMC5267755 DOI: 10.1186/s13321-016-0188-5] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2016] [Accepted: 12/28/2016] [Indexed: 01/15/2023] Open
Abstract
Background
Natural products have increasingly attracted much attention as a valuable resource for the development of anticancer medicines due to the structural novelty and good bioavailability. This necessitates a comprehensive database for the natural products and the fractional extracts whose anticancer activities have been verified. Description NPCARE (http://silver.sejong.ac.kr/npcare) is a publicly accessible online database of natural products and fractional extracts for cancer regulation. At NPCARE, one can explore 6578 natural compounds and 2566 fractional extracts isolated from 1952 distinct biological species including plants, marine organisms, fungi, and bacteria whose anticancer activities were validated with 1107 cell lines for 34 cancer types. Each entry in NPCARE is annotated with the cancer type, genus and species names of the biological resource, the cell line used for demonstrating the anticancer activity, PubChem ID, and a wealth of information about the target gene or protein. Besides the augmentation of plant entries up to 743 genus and 197 families, NPCARE is further enriched with the natural products and the fractional extracts of diverse non-traditional biological resources. Conclusions NPCARE is anticipated to serve as a dominant gateway for the discovery of new anticancer medicines due to the inclusion of a large number of the fractional extracts as well as the natural compounds isolated from a variety of biological resources. Electronic supplementary material The online version of this article (doi:10.1186/s13321-016-0188-5) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Hwanho Choi
- Department of Bioscience and Biotechnology, Institute of Anticancer Medicine Development, Sejong University, 209 Neungdong-ro, Kwangjin-gu, Seoul, 05006 Korea
| | - Sun Young Cho
- College of Korean Medicine, Dongguk University, 27 Dongguk-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do 10326 Korea
| | - Ho Jeong Pak
- Department of Obstetrics and Gynecology, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Sucho-gu, Seoul, 06591 Korea
| | - Youngsoo Kim
- Department of Biological Sciences, KAIST, 291 Daehak-ro, Yuseong-gu, Daejeon, 34141 Korea
| | - Jung-Yun Choi
- Graduate School of Medical Science and Engineering, KAIST, 291 Daehak-ro, Yuseong-gu, Daejeon, 34141 Korea
| | - Yoon Jae Lee
- Department of Korean Gynecology, Jaseng Hospital of Korean Medicine, 858 Eonju-ro, Gangnam-gu, Seoul, 06017 Korea
| | - Byung Hee Gong
- College of Korean Medicine, Wonkwang University, 460 Iksandae-ro, Iksan, Jeonbuk 54538 Korea
| | - Yeon Seok Kang
- College of Korean Medicine, Wonkwang University, 460 Iksandae-ro, Iksan, Jeonbuk 54538 Korea
| | - Taehoon Han
- WiFun Team, Nexon, 7 Pangyo-ro 256 gil, Bundang-gu, Seongnam-si, Gyeonggi-do 13487 Korea
| | - Geunbae Choi
- Hanvit Dental-Medical Hospital, 396 Seowon-daero, Wonju, Gangwon-do 26484 Korea
| | - Yeeun Cho
- Department of Clinical Korean Medicine, Kyung Hee University Korean Medicine Hospital, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul, 02447 Korea
| | - Soomin Lee
- Department of Clinical Korean Medicine, Kyung Hee University Korean Medicine Hospital, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul, 02447 Korea
| | - Dekwoo Ryoo
- Department of Clinical Korean Medicine, Kyung Hee University Korean Medicine Hospital, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul, 02447 Korea
| | - Hwangseo Park
- Department of Bioscience and Biotechnology, Institute of Anticancer Medicine Development, Sejong University, 209 Neungdong-ro, Kwangjin-gu, Seoul, 05006 Korea
| |
Collapse
|
22
|
Mahaddalkar T, Manchukonda N, Choudhary S, Cheriyamundath S, Mohanpuria N, Kantevari S, Lopus M. Subtle Alterations in Microtubule Assembly Dynamics by Br-TMB-Noscapine Strongly Suppress Triple-Negative Breast Cancer Cell Viability Without Mitotic Arrest. ChemistrySelect 2016. [DOI: 10.1002/slct.201600959] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Affiliation(s)
- Tejashree Mahaddalkar
- Experimental Cancer Therapeutics and Chemical Biology, UM-DAE Centre for Excellence in Basic Sciences; University of Mumbai Kalina Campus; Mumbai- 400098 India
| | - Naresh Manchukonda
- Organic Chemistry Division-II (CPC Division); CSIR-Indian Institute of Chemical Technology; Hyderabad, Telangana India
| | - Sinjan Choudhary
- Experimental Cancer Therapeutics and Chemical Biology, UM-DAE Centre for Excellence in Basic Sciences; University of Mumbai Kalina Campus; Mumbai- 400098 India
| | - Sanith Cheriyamundath
- Experimental Cancer Therapeutics and Chemical Biology, UM-DAE Centre for Excellence in Basic Sciences; University of Mumbai Kalina Campus; Mumbai- 400098 India
| | - Neha Mohanpuria
- Experimental Cancer Therapeutics and Chemical Biology, UM-DAE Centre for Excellence in Basic Sciences; University of Mumbai Kalina Campus; Mumbai- 400098 India
| | - Srinivas Kantevari
- Organic Chemistry Division-II (CPC Division); CSIR-Indian Institute of Chemical Technology; Hyderabad, Telangana India
| | - Manu Lopus
- Experimental Cancer Therapeutics and Chemical Biology, UM-DAE Centre for Excellence in Basic Sciences; University of Mumbai Kalina Campus; Mumbai- 400098 India
| |
Collapse
|
23
|
Goodin S, Barbour S, Song J, Berrak E, Cox D. Safety and tolerability of eribulin mesylate in patients with pretreated metastatic breast cancer. Am J Health Syst Pharm 2015; 72:2150-6. [DOI: 10.2146/ajhp140773] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Affiliation(s)
- Susan Goodin
- Robert Wood Johnson Medical School, Rutgers Cancer Institute of New Jersey, New Brunswick
| | | | - James Song
- Oncology, Eisai Inc., Woodcliff Lakes, NJ
| | | | - David Cox
- Medical Affairs, Ipsen Biopharmaceuticals, Basking Ridge, NJ; at the time of writing he was Group Director, Oncology Medical Strategy, Eisai Inc
| |
Collapse
|
24
|
Dell'Ova M, De Maio E, Guiu S, Roca L, Dalenc F, Durigova A, Pinguet F, Bekhtari K, Jacot W, Pouderoux S. Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study. BMC Cancer 2015; 15:659. [PMID: 26449988 PMCID: PMC4599752 DOI: 10.1186/s12885-015-1673-3] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2015] [Accepted: 10/01/2015] [Indexed: 11/24/2022] Open
Abstract
BACKGROUND Our retrospective, international study aimed at evaluating the activity and safety of eribulin mesylate (EM) in pretreated metastatic breast cancer (MBC) in a routine clinical setting. METHODS Patients treated with EM for a locally advanced or MBC between March 2011 and January 2014 were included in the study. Clinical and biological assessment of toxicity was performed at each visit. Tumour response was assessed every 3 cycles of treatment. A database was created to collect clinical, pathological and treatment data. RESULTS Two hundred and fifty-eight patients were included in the study. Median age was 59 years old. Tumours were Hormone Receptor (HR)-positive (73.3 %) HER2-positive (10.2 %), and triple negative (TN, 22.5 %). 86.4 % of the patients presented with visceral metastases, mainly in the liver (67.4 %). Median previous metastatic chemotherapies number was 4 [1-9]. Previous treatments included anthracyclines and/or taxanes (100 %) and capecitabine (90.7 %). Median number of EM cycles was 5 [1-19]. The relative dose intensity was 0.917. At the time of analysis (median follow-up of 13.9 months), 42.3 % of the patients were still alive. The objective response rate was 25.2 % (95 %CI: 20-31) with a 36.1 % clinical benefit rate (CBR). Median time to progression (TTP) and overall survival were 3.97 (95 %CI: 3.25-4.3) and 11.2 (95 %CI: 9.3-12.1) months, respectively. One- and 2-year survival rates were 45.5 and 8.5 %, respectively. In multivariate analysis, HER2 positivity (HR = 0.29), the presence of lung metastases (HR = 2.49) and primary taxanes resistance (HR = 2.36) were the only three independent CBR predictive factors, while HR positivity (HR = 0.67), the presence of lung metastases (HR = 1.52) and primary taxanes resistance (HR = 1.50) were the only three TTP independent prognostic factors. Treatment was globally well tolerated. Most common grade 3-4 toxicities were neutropenia (20.9 %), peripheral neuropathy (3.9 %), anaemia (1.6 %), liver dysfunction (0.8 %) and thrombocytopenia (0.4 %). Thirteen patients (5 %) developed febrile neutropenia. CONCLUSION EM is an effective new option in heavily pretreated MBC, with a favourable efficacy/safety ratio in a clinical practice setting. Our results comfort the use of this new molecule and pledge for the evaluation of EM-trastuzumab combination in this setting. Tumour biology, primary taxanes sensitivity and metastatic sites could represent useful predictive and prognostic factors.
Collapse
Affiliation(s)
- Mélodie Dell'Ova
- Département de Pharmacie Clinique, Institut régional du Cancer de Montpellier (ICM), 208, rue des Apothicaires, 34298, Montpellier Cedex 5, France.
| | - Eléonora De Maio
- Medical Oncology Department, Institut Claudius Regaud, IUCT- Oncopole, Toulouse, France.
| | - Séverine Guiu
- Medical Oncology Department, Centre Georges-François Leclerc, Dijon, France.
- Breast Center (CePO), University Hospital CHUV, Rue du Bugnon 46, 1011, Lausanne, Switzerland.
| | - Lise Roca
- Département de Biostatistiques, Institut régional du Cancer de Montpellier (ICM), 208, rue des Apothicaires, 34298, Montpellier Cedex 5, France.
| | - Florence Dalenc
- Medical Oncology Department, Institut Claudius Regaud, IUCT- Oncopole, Toulouse, France.
| | - Anna Durigova
- Département d'Oncologie Médicale, Institut régional du Cancer de Montpellier (ICM), 208, rue des Apothicaires, 34298, Montpellier Cedex 5, France.
- Medical Oncology Department, University Hospital of Geneva, Gabrielle-Perret-Gentil 4, 1211, Geneva, Switzerland.
| | - Frédéric Pinguet
- Département de Pharmacie Clinique, Institut régional du Cancer de Montpellier (ICM), 208, rue des Apothicaires, 34298, Montpellier Cedex 5, France.
| | - Khedidja Bekhtari
- Département de Pharmacie Clinique, Institut régional du Cancer de Montpellier (ICM), 208, rue des Apothicaires, 34298, Montpellier Cedex 5, France.
| | - William Jacot
- Département d'Oncologie Médicale, Institut régional du Cancer de Montpellier (ICM), 208, rue des Apothicaires, 34298, Montpellier Cedex 5, France.
| | - Stéphane Pouderoux
- Département d'Oncologie Médicale, Institut régional du Cancer de Montpellier (ICM), 208, rue des Apothicaires, 34298, Montpellier Cedex 5, France.
| |
Collapse
|
25
|
Harvey AL, Edrada-Ebel R, Quinn RJ. The re-emergence of natural products for drug discovery in the genomics era. Nat Rev Drug Discov 2015; 14:111-29. [PMID: 25614221 DOI: 10.1038/nrd4510] [Citation(s) in RCA: 1508] [Impact Index Per Article: 167.6] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Natural products have been a rich source of compounds for drug discovery. However, their use has diminished in the past two decades, in part because of technical barriers to screening natural products in high-throughput assays against molecular targets. Here, we review strategies for natural product screening that harness the recent technical advances that have reduced these barriers. We also assess the use of genomic and metabolomic approaches to augment traditional methods of studying natural products, and highlight recent examples of natural products in antimicrobial drug discovery and as inhibitors of protein-protein interactions. The growing appreciation of functional assays and phenotypic screens may further contribute to a revival of interest in natural products for drug discovery.
Collapse
Affiliation(s)
- Alan L Harvey
- 1] Research and Innovation Support, Dublin City University, Dublin 9, Ireland. [2] Strathclyde Institute of Pharmacy and Biomedical Science, University of Strathclyde, Glasgow G4 0NR, UK
| | - RuAngelie Edrada-Ebel
- Strathclyde Institute of Pharmacy and Biomedical Science, University of Strathclyde, Glasgow G4 0NR, UK
| | - Ronald J Quinn
- Eskitis Institute for Drug Discovery, Griffith University, Brisbane, Queensland 4111, Australia
| |
Collapse
|
26
|
Dasari B, Jimmidi R, Arya P. Selected hybrid natural products as tubulin modulators. Eur J Med Chem 2014; 94:497-508. [PMID: 25455639 DOI: 10.1016/j.ejmech.2014.10.062] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2014] [Revised: 10/10/2014] [Accepted: 10/20/2014] [Indexed: 01/09/2023]
Abstract
Modulators of microtubule dynamics have received increasing attention because of their potential to stop cancer growth. Although it belongs to the category of complex protein-protein interactions (PPIs), which are generally considered difficult to modulate through small molecules, the use of microtubule is considered a well-validated target. There are a number of bioactive natural products and related compounds that are currently in use as drugs or in clinical trials as next generation anti-cancer agents. The present review article is focused on two such bioactive natural products, epothilone and halichondrin B, and covers some of the key papers published after 2005 that outline various synthetic approaches to obtain next generation structural analogs as well as the synthesis of hybrid compounds.
Collapse
Affiliation(s)
- Bhanudas Dasari
- Dr. Reddy's Institute of Life Sciences (DRILS), University of Hyderabad Campus, Gachibowli, Hyderabad 500046, Telangana, India
| | - Ravikumar Jimmidi
- Dr. Reddy's Institute of Life Sciences (DRILS), University of Hyderabad Campus, Gachibowli, Hyderabad 500046, Telangana, India
| | - Prabhat Arya
- Dr. Reddy's Institute of Life Sciences (DRILS), University of Hyderabad Campus, Gachibowli, Hyderabad 500046, Telangana, India.
| |
Collapse
|
27
|
Fife CM, McCarroll JA, Kavallaris M. Movers and shakers: cell cytoskeleton in cancer metastasis. Br J Pharmacol 2014; 171:5507-23. [PMID: 24665826 DOI: 10.1111/bph.12704] [Citation(s) in RCA: 367] [Impact Index Per Article: 36.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2013] [Revised: 03/14/2014] [Accepted: 03/18/2014] [Indexed: 12/11/2022] Open
Abstract
UNLABELLED Metastasis is responsible for the greatest number of cancer deaths. Metastatic disease, or the movement of cancer cells from one site to another, is a complex process requiring dramatic remodelling of the cell cytoskeleton. The various components of the cytoskeleton, actin (microfilaments), microtubules (MTs) and intermediate filaments, are highly integrated and their functions are well orchestrated in normal cells. In contrast, mutations and abnormal expression of cytoskeletal and cytoskeletal-associated proteins play an important role in the ability of cancer cells to resist chemotherapy and metastasize. Studies on the role of actin and its interacting partners have highlighted key signalling pathways, such as the Rho GTPases, and downstream effector proteins that, through the cytoskeleton, mediate tumour cell migration, invasion and metastasis. An emerging role for MTs in tumour cell metastasis is being unravelled and there is increasing interest in the crosstalk between key MT interacting proteins and the actin cytoskeleton, which may provide novel treatment avenues for metastatic disease. Improved understanding of how the cytoskeleton and its interacting partners influence tumour cell migration and metastasis has led to the development of novel therapeutics against aggressive and metastatic disease. LINKED ARTICLES This article is part of a themed section on Cytoskeleton, Extracellular Matrix, Cell Migration, Wound Healing and Related Topics. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2014.171.issue-24.
Collapse
Affiliation(s)
- C M Fife
- Tumour Biology and Targeting Program, Children's Cancer Institute Australia Lowy Cancer Research Centre, UNSW Australia, Randwick, NSW, Australia; Australian Centre for NanoMedicine, UNSW Australia, Sydney, NSW, Australia
| | | | | |
Collapse
|
28
|
García-Hevia L, Fernández F, Grávalos C, García A, Villegas JC, Fanarraga ML. Nanotube interactions with microtubules: implications for cancer medicine. Nanomedicine (Lond) 2014; 9:1581-8. [DOI: 10.2217/nnm.14.92] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
Carbon nanotubes (CNTs) and microtubules are both hollow nanofibers and have similar dimensions; they both self-assemble and form bundles. These common features prompt their association into biosynthetic polymers in vitro and in vivo. Unlike CNTs, microtubules are highly dynamic protein polymers essential for cell proliferation and migration. Interaction between these filaments inside live cells leads to microtubule dysfunction, mitotic arrest and cell death. Thus, CNTs behave as spindle poisons, same as taxanes, vinca alkaloids or epotilones. Recent findings support the idea that CNTs represent a ground-breaking type of synthetic microtubule-stabilizing agents that could play a pivotal role in future cancer treatments in combination to traditional antineoplastic drugs. Here we review the potential use of CNTs in cancer medicine.
Collapse
Affiliation(s)
- Lorena García-Hevia
- Departamento de Biología Molecular, Universidad de Cantabria-IDIVAL, Santander 39011, Spain
| | - Fidel Fernández
- Ciencias Médicas y Quirúrgicas, Universidad de Cantabria-IDIVAL, Santander 39011, Spain
| | - Cristina Grávalos
- Servicio de Oncología, Hospital Universitario Marqués de Valdecilla, Santander 39008, Spain
| | - Almudena García
- Servicio de Oncología, Hospital Universitario Marqués de Valdecilla, Santander 39008, Spain
| | - Juan C Villegas
- Departamento de Anatomía y Biología Celular, Universidad de Cantabria-IDIVAL, Santander 39011, Spain
| | - Mónica L Fanarraga
- Departamento de Biología Molecular, Universidad de Cantabria-IDIVAL, Santander 39011, Spain
| |
Collapse
|
29
|
Current status on marine products with reversal effect on cancer multidrug resistance. Mar Drugs 2012; 10:2312-2321. [PMID: 23170086 PMCID: PMC3497025 DOI: 10.3390/md10102312] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2012] [Revised: 09/13/2012] [Accepted: 09/29/2012] [Indexed: 01/03/2023] Open
Abstract
The resistance of tumor cells to a broad range of anticancer agents continues to be a problem for the success of cancer chemotherapy. Multidrug resistance (MDR) is due in part to three drug transporter proteins: ABCB1/P-glycoprotein (P-gp), ABCC1/multidrug resistance protein 1 (MRP1) and ABCG2/breast cancer resistance protein (BCRP). These transporters are part of the ATP-binding cassette (ABC) superfamily, whose members function as ATP-dependent drug-efflux pumps. Their activity can be blocked by various drugs such as verapamil (calcium channel blocker) and cyclosporin A (immunosuppressive agent), etc. These compounds are called MDR modulators or reversals. This review highlights several marine natural products with reversal effect on multidrug resistance in cancer, including agosterol A, ecteinascidin 743, sipholane triterpenoids, bryostatin 1, and welwitindolinones.
Collapse
|